Author/Editor
Dave Lashmet
Publisher
Stansberry Research
Description
Monthly small-cap investing newsletter that aims to have a “venture capital” investing mindset, looking for high-risk opportunities for dramatic gains, primarily in tech or biotech. Listed as “Very Speculative” portfolio.
Overall Rating
Rating: 2.5/5. From 14 votes.
Please wait...
2.7
Rating from 45 votes
If you’ve subscribed to Stansberry Venture Technology, please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.
Investment Performance
Rating from 12 votes
Rating: 2.8/5. From 12 votes.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 2 Votes
- 3 Stars 4 Votes
- 2 Stars 3 Votes
- 1 Stars 2 Votes
Quality Of Writing/Analysis
Rating from 9 votes
Rating: 2.9/5. From 9 votes.
Please wait...
Your vote
- 5 Stars 0 Votes
- 4 Stars 3 Votes
- 3 Stars 3 Votes
- 2 Stars 2 Votes
- 1 Stars 1 Votes
Value For Price
Rating from 10 votes
Rating: 2.6/5. From 10 votes.
Please wait...
Your vote
- 5 Stars 0 Votes
- 4 Stars 2 Votes
- 3 Stars 4 Votes
- 2 Stars 2 Votes
- 1 Stars 2 Votes
Customer Service
Rating from 14 votes
Rating: 2.5/5. From 14 votes.
Please wait...
Your vote
- 5 Stars 3 Votes
- 4 Stars 1 Votes
- 3 Stars 2 Votes
- 2 Stars 2 Votes
- 1 Stars 6 Votes
Lashmet tends to be overenthusiastic about his picks. I was one of the first subscribers to the service he started before Venture. He had a very strong tout for TTPH in the 40’s, It had sailed through trials 1 and 2, and #3 was going to be a slam dunk, absolute certainty. Of course, #3 was a complete failure. The bottom fell out, as the stock dropped to 4. There was no apology. That was enough for me with Lashmet. I suppose some of his picks have done OK, but once burned, twice shy.
Then why a 3 rating???????